Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab-Reference-Cited by-同舟云学术

Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab

Published:2024-02-12 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Nixon Andrew B.,Liu Yingmiao,Yang Qian,Luo Bin,Starr Mark D.,Brady John C.,Kelly Wm Kevin,Beltran Himisha^ORCID,Morris Michael J.^ORCID,George Daniel J.^ORCID,Armstrong Andrew J.^ORCID,Halabi Susan^ORCID

Funder

United States Department of Defense | U.S. Army

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Prostate Cancer Foundation

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41391-024-00794-3.pdf

Reference42 articles.

1. Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479–99. https://doi.org/10.1146/annurev-med-051517-011947.

2. Gourdin T. Recent progress in treating advanced prostate cancer. Curr Opin Oncol. 2020;32:210–5. https://doi.org/10.1097/CCO.0000000000000624.

3. Petrylak DP, Tangen CM, Hussain MH, Lara PN,Jr., Jones JA, Taplin ME. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. https://doi.org/10.1056/NEJMoa041318.

4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. https://doi.org/10.1056/NEJMoa040720.

5. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. https://doi.org/10.1016/S0140-6736(10)61389-X.